Advanced in Agranulocytosis

Dr. Timothy R. Wassenaar

Hematology Oncology | Hematology | Oncology

Prohealth Medical Group Inc

1185 Corporate Ctr Dr, Suite 175,

Oconomowoc, WI

Accepting New Patients

Offers Telehealth

Advanced in Agranulocytosis

Prohealth Medical Group Inc

1185 Corporate Ctr Dr, Suite 175,

Oconomowoc, WI

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Timothy Wassenaar is a Hematologist Oncology specialist and a Hematologist in Oconomowoc, Wisconsin. Dr. Wassenaar is rated as an Advanced provider by MediFind in the treatment of Agranulocytosis. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Adult Immune Thrombocytopenia, Bone Marrow Aspiration, and Tissue Biopsy. Dr. Wassenaar is currently accepting new patients.

His clinical research consists of co-authoring 7 peer reviewed articles and participating in 112 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology Oncology

Hematology

Oncology

Licenses

Internal Medicine in WI

Hospital Affiliations

Oconomowoc Memorial Hospital

Waukesha Memorial Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem BCBS

Blue Cross Blue Shield

Change Healthcare

OTHER MEDICARE
OTHER MEDICARE PART D

Children's Community Health

Cigna

Dean Health

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Humana

HMO
INDEMNITY
POS
PPO

Managed Medicaid

OTHER MANAGED MEDICAID

Medicaid

OTHER MEDICAID
STATE MEDICAID

Network Health

Quartz

Quartz Health Plan

HMO
MANAGED MEDICAID PLAN
MEDICARE MAPD
OTHER COMMERCIAL
OTHER MEDICARE PART D

UnitedHealthcare

Walgreens

MEDICARE DISCOUNT CARD
MEDICARE PDP
OTHER MEDICARE

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 12 Less Insurance Carriers -

Locations

PROHEALTH MEDICAL GROUP INC
1185 Corporate Ctr Dr, Suite 175, Oconomowoc, WI 53066

Call: 262-928-8400

Other Locations

PROHEALTH MEDICAL GROUP INC
N16w24131 Riverwood Dr, Suite 2200b, Waukesha, WI 53188

Call: 262-696-0765

PROHEALTH MEDICAL GROUP INC
N17w24100 Riverwood Dr, Waukesha, WI 53188

Call: 262-928-4704

PROHEALTH MEDICAL GROUP INC
791 Summit Ave, Oconomowoc, WI 53066

Call: 262-569-0554

PROHEALTH MEDICAL GROUP INC
725 American Ave, Waukesha, WI 53188

Call: 262-928-1000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

112 Clinical Trials

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Biological, Radiation, Other

Study Drugs: Cisplatin, Nivolumab

Study Phase: Phase 3

[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients With Newly Diagnosed Metastatic Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Drug

Study Drug: F-18 16 Alpha-Fluoroestradiol

Study Phase: Phase 2

MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Drug

Study Drugs: Avelumab, Cabozantinib S-malate

Study Phase: Phase 3

Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Biological, Procedure

Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate

Study Phase: Phase 2/Phase 3

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer

Enrollment Status: Suspended

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Biological, Radiation

Study Drugs: Carboplatin, Ipilimumab, Nab-paclitaxel, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed

Study Phase: Phase 2/Phase 3

Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Radiation, Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 3

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Biological

Study Drugs: Olaparib, Pembrolizumab

Study Phase: Phase 2

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab, Sargramostim

Study Phase: Phase 2/Phase 3

A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Biological, Drug

Study Drugs: Carboplatin, Nivolumab, Paclitaxel

Study Phase: Phase 3

A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Drug

Study Drug: Erlotinib Hydrochloride

Study Phase: Phase 3

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Drug, Biological

Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax

Study Phase: Phase 3

Molecular Analysis for Therapy Choice (MATCH)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib

Study Phase: Phase 2

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Drug, Procedure, Radiation

Study Drug: Atezolizumab

Study Phase: Phase 3

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Biological

Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium

Study Phase: Phase 3

A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Biological

Study Drugs: Atezolizumab, Bevacizumab, Carboplatin, Cetuximab, Cisplatin, Docetaxel

Study Phase: Phase 2/Phase 3

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Biological

Study Drugs: Gemcitabine Hydrochloride, Pembrolizumab

Study Phase: Phase 2

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug

Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide

Study Phase: Phase 2

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Biological, Drug

Study Phase: Not Applicable

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 10, 2026

Intervention Type: Drug, Other

Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate

Study Phase: Phase 3

Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin

Enrollment Status: Completed

Publish Date: February 06, 2026

Intervention Type: Other, Biological, Radiation

Study Drugs: Cetuximab, Durvalumab

Study Phase: Phase 2/Phase 3

CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 05, 2026

Intervention Type: Other, Drug

Study Drugs: Enzalutamide, Rucaparib Camsylate, Leuprolide Acetate, Goserelin Acetate, Degarelix

Study Phase: Phase 3

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Enrollment Status: Active_not_recruiting

Publish Date: February 02, 2026

Intervention Type: Other, Procedure, Drug

Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin

Study Phase: Phase 3

A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma

Enrollment Status: Suspended

Publish Date: February 02, 2026

Intervention Type: Procedure, Drug, Radiation, Other

Study Drugs: Lomustine, Temozolomide

Study Phase: Phase 3

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

Enrollment Status: Active_not_recruiting

Publish Date: February 02, 2026

Intervention Type: Drug, Biological, Other

Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax

Study Phase: Phase 3

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)

Enrollment Status: Active_not_recruiting

Publish Date: January 29, 2026

Intervention Type: Drug

Study Drugs: Pirtobrutinib, Venetoclax, Rituximab

Study Phase: Phase 3

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Drug

Study Drugs: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine

Study Phase: Phase 2/Phase 3

A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Procedure, Drug, Radiation

Study Drugs: Capecitabine, Fluorouracil, Mitomycin

Study Phase: Phase 2

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Biological, Drug

Study Drugs: Acalabrutinib, Bendamustine, Bendamustine Hydrochloride, Cytarabine, Rituximab

Study Phase: Phase 2

Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Diagnostic test

Study Phase: Not Applicable

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Procedure

Study Phase: Phase 3

Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS for Resected Metastatic Brain Disease

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Radiation, Procedure, Other

Study Phase: Phase 3

FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Procedure

Study Phase: Phase 2

A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Biological, Procedure

Study Drug: Rituximab

Study Phase: Phase 3

Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Diagnostic test

Study Phase: Not Applicable

Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

Enrollment Status: Active_not_recruiting

Publish Date: January 22, 2026

Intervention Type: Drug, Radiation

Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine

Study Phase: Phase 3

A Single Arm Phase II Study of Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016

Enrollment Status: Completed

Publish Date: January 20, 2026

Intervention Type: Drug

Study Drugs: Palbociclib, Tamoxifen

Study Phase: Phase 2

Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Enrollment Status: Suspended

Publish Date: January 14, 2026

Intervention Type: Other, Procedure, Drug, Radiation

Study Drug: Cisplatin

Study Phase: Phase 2/Phase 3

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Enrollment Status: Active_not_recruiting

Publish Date: January 14, 2026

Intervention Type: Drug, Procedure

Study Drugs: Carboplatin, Letrozole, Paclitaxel

Study Phase: Phase 3

A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

Enrollment Status: Completed

Publish Date: January 12, 2026

Intervention Type: Drug

Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel

Study Phase: Phase 3

A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Enrollment Status: Completed

Publish Date: December 30, 2025

Intervention Type: Other, Procedure, Biological, Drug

Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab

Study Phase: Phase 3

Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

Enrollment Status: Active_not_recruiting

Publish Date: December 22, 2025

Intervention Type: Other, Dietary supplement, Drug

Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan

Study Phase: Phase 3

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Enrollment Status: Active_not_recruiting

Publish Date: December 19, 2025

Intervention Type: Other, Drug

Study Drug: Crizotinib

Study Phase: Phase 3

Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)

Enrollment Status: Active_not_recruiting

Publish Date: December 19, 2025

Intervention Type: Other, Procedure, Drug, Radiation

Study Phase: Not Applicable

A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: December 18, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate

Study Phase: Phase 3

A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma

Enrollment Status: Completed

Publish Date: December 11, 2025

Intervention Type: Biological

Study Drugs: Bevacizumab, Ipilimumab

Study Phase: Phase 2

A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: December 05, 2025

Intervention Type: Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 2

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: December 04, 2025

Intervention Type: Drug, Biological, Procedure, Other, Radiation

Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine

Study Phase: Phase 3

View 49 Less Clinical Trials

7 Total Publications

Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.

Journal: Cancer research communications

Published: January 17, 2023

View All 7 Publications

Similar Doctors

Advanced in Agranulocytosis

Dr. Syed N. Haider

Hematology Oncology | Hematology | Oncology

Advanced in Agranulocytosis

Dr. Syed N. Haider

Hematology Oncology | Hematology | Oncology

Froedtert South Inc

9555 76th St,

Pleasant Prairie, WI

(44.7 miles away)

262-577-8300

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Syed Haider is a Hematologist Oncology specialist and a Hematologist in Pleasant Prairie, Wisconsin. Dr. Haider is rated as a Distinguished provider by MediFind in the treatment of Agranulocytosis. His top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, and Paget Disease of the Breast. Dr. Haider is currently accepting new patients.

Advanced in Agranulocytosis

Dr. Harvey E. Einhorn

Hematology Oncology | Hematology | Oncology

Advanced in Agranulocytosis

Dr. Harvey E. Einhorn

Hematology Oncology | Hematology | Oncology

Swedishamerican Hospital

3505 N Bell School Rd,

Rockford, IL

(58.1 miles away)

779-696-0300

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Harvey Einhorn is a Hematologist Oncology specialist and a Hematologist in Rockford, Illinois. Dr. Einhorn is rated as a Distinguished provider by MediFind in the treatment of Agranulocytosis. His top areas of expertise are Lung Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Pleuropulmonary Blastoma. Dr. Einhorn is currently accepting new patients.

Advanced in Agranulocytosis

Dr. H M. Matthews

Hematology Oncology | Hematology | Oncology

Advanced in Agranulocytosis

Dr. H M. Matthews

Hematology Oncology | Hematology | Oncology

1621 N Taylor Dr, Suite 100,

Sheboygan, WI

(60.1 miles away)

920-458-7433

Languages Spoken:

English

See accepted insurances

Accepting New Patients

H Matthews is a Hematologist Oncology specialist and a Hematologist in Sheboygan, Wisconsin. Dr. Matthews is rated as an Advanced provider by MediFind in the treatment of Agranulocytosis. His top areas of expertise are Myelodysplastic Syndrome (MDS), Childhood Iron Deficiency Anemia, Intraductal Papilloma, and Small Cell Lung Cancer (SCLC). Dr. Matthews is currently accepting new patients.

VIEW MORE AGRANULOCYTOSIS DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wassenaar's expertise for a condition

ConditionClose